Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The immune response differences of rats induced using RBD3-Fc mRNA vaccines inoculated intradermally by NFIS and intramuscularly by needles

ABSTRACT: We have employed a single cell sequencing approach using 10× chromium microfluidic system to further illustrate the effect of inoculation routes on T cell immune responses induced by the mRNA-LNP vaccine and naked mRNA vaccine. Rat splenocytes were harvested at week 6. CD45+ splenocytes were separated and captured as immune cells using flow cytometry, then analyzed using scRNA-seq. THis study revealed the advantages of NIFS delivery, which evoked potent T cell responses.

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE288793 | GEO | 2025/02/06

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Synergistic Effect of Nucleoside Modification and Ionizable Lipid Composition on Translation and Immune Responses to mRNA Vaccines

Project description:Lipid nanoparticle (LNP) structural components can impact the safety and immunogenicity of mRNA vaccines. Here we examine the mechanisms contributing to the performance of mRNA-LNP vaccines by exploring the impact of nucleoside modifications and LNP components on translational efficiency, innate immune activation, and immunogenicity, by employing in vitro (cell culture) and in vivo (mice and cynomolgus macaques) models. Our data reveal several molecular and immunological parameters affected by nucleoside modification. These include: i) a sequence-dependent increase in antigen expression; ii) decreased induction of genes associated with antiviral activity and RNA degradation in modified mRNA compared with unmodified mRNA; iii) reduced innate immune recognition of nucleoside-modified mRNA, accompanied by lower levels of inflammatory cytokines and chemokines in non-human primates; and iv) a synergistic effect of the mRNA and ionizable lipid composition on the immune activation triggered by the mRNA-LNP formulation. Our data show that changes in the LNP composition, independent from whether the mRNA is modified or unmodified, caused differential expression of genes associated with innate and antiviral immunity. For instance, modification of mRNA was able to silence the innate immune signatures more efficiently for certain LNPs but not others. We believe these findings offer valuable insights into mRNA vaccine function and offer strategies for enhancing vaccine efficacy and reducing the reactogenicity of next generation mRNA vaccines.

2025-09-11 | GSE303153 | GEO

Multivalent vaccines demonstrate immunogenicity and protect against Coxiella burnetii aerosol challenge

Project description:C57BL/6 mice were immunized with Coxiella burnetii vaccine Q-VAX (Seqirus) and monitored for up to 83 days post immunization. Two different routes of immunization were observed - subcutaneous and intramuscular. Subcutaneously immunized animals were boosted on day 67.

2023-04-11 | GSE229293 | GEO

A platform for the recombinant production of Group A Streptococcus glycoconjugate vaccines

Project description:Strep A are human-exclusive bacterial pathogens killing annually more than 500,000 patients, and no current licensed vaccine exists. Strep A bacteria are highly diverse, but all produce an essential, abundant, and conserved main surface carbohydrate, the Group A Carbohydrate (GAC). GAC contains a rhamnose polysaccharide (RhaPS) backbone, which is a validated universal vaccine candidate. RhaPS vaccine candidate production is currently limited to chemical routes. We engineered the GAC synthesis route to enable the industry standard recombinant production route to couple RhaPS to selected carrier proteins. The integrity of the correct chemical structure of the glycoconjugate vaccines was confirmed by NMR spectroscopy and mass spectrometry. Purified IdeS-RhaPS and NanA-RhaPS produce carbohydrate specific antibodies in mice and rabbits confirming the recombinantly produced RhaPS glycoconjugates as valuable vaccine candidates. We provide a promising route to the production of tailor-made low-cost glycoconjugate vaccines against Strep A and other bacterial pathogens.

2025-04-22 | PXD037039 | Pride

Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity

Project description:Lipid nanoparticles (LNPs) for mRNA delivery have advanced significantly, but LNP-mediated DNA delivery still faces clinical challenges. This study compared various LNP formulations for delivering DNA-encoded biologics, assessing their expression efficacy and the protective immunity generated by LNP-encapsulated DNA in different models. The LNP formulation used in Moderna’s Spikevax mRNA vaccine (LNP-M) demonstrated a stable nanoparticle structure, high expression efficiency, and low toxicity. Notably, a DNA vaccine encoding the spike protein, delivered via LNP-M, induced stronger antigen-specific antibody and T cell immune responses compared to electroporation. Single-cell RNA sequencing (scRNA-seq) analysis revealed that the LNP-M/pSpike vaccine enhanced CD80 activation signaling in CD8+ T cells, NK cells, macrophages, and DCs, while reducing the immunosuppressive signals. The enrichment of TCR and BCR by LNP-M/pSpike suggested an increase in immune response specificity and diversity. Additionally, LNP-M effectively delivered DNA-encoded antigens, such as mouse PD-L1 and p53R172H, or monoclonal antibodies targeting mouse PD-1 and human p53R282W. This approach inhibited tumor growth or metastasis in several mouse models. The long-term anti-tumor effects of LNP-M-delivered anti-p53R282W antibody relied on memory CD8+ T cell responses and enhanced MHC-I signaling from APCs to CD8+ T cells. These results highlight LNP-M as a promising and effective platform for delivering DNA-based vaccines and cancer immunotherapies.

2025-01-22 | GSE272803 | GEO

Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 high-pathogenicity avian influenza virus with reduced adverse reactions (using dendritic cell of lymph node)

Project description:Messenger RNA vaccines based on lipid nanoparticles (mRNA-LNPs) are promising vaccine modalities. However, mRNA-LNP vaccines frequently cause adverse reactions such as swelling and fever in humans, partly due to the inflammatory nature of LNP. Modification of the ionizable lipids used in LNP is one approach to avoid these adverse reactions. Herein, we report the development of mRNA-LNP vaccines with better protective immunity and reduced adverse reactions using LNP, including SS-cleavable and pH-activated lipid-like materials with oleic acid (ssPalmO) as an ionizable lipid (LNPssPalmO). We used mRNA expressing H5N1 subtype high-pathogenicity avian influenza virus-derived hemagglutinin or neuraminidase to generate mRNA-LNP vaccines against H5N1 influenza. Compared with conventional LNP, mRNA-LNPssPalmO induced comparable antigen-specific antibodies and better IFN--producing Th1 responses in mice. Both mRNA-LNPssPalmO and conventional mRNA-LNP conferred strong protection against homologous H5N1 virus challenge. In addition, mRNA-LNPssPalmO showed better cross-protection against heterologous H5N1 virus challenge compared to conventional mRNA-LNPs. Furthermore, we observed that mRNA-LNPssPalmO induced less inflammatory responses (e.g., inflammatory cytokine production and vascular hyperpermeability) and fewer adverse reactions (e.g., weight loss and fever) compared with conventional mRNA-LNP. These results suggest that mRNA-LNPssPalmO would be a safe alternative to conventional vaccines to overcome mRNA-LNP vaccine hesitancy.

2025-03-05 | GSE279744 | GEO

Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 high-pathogenicity avian influenza virus with reduced adverse reactions (using whole lymph node)

2025-03-05 | GSE279743 | GEO

Prototype LNP-mRNA vaccine candidates [SC_RNAseq]

Project description:Prototype LNP-mRNA vaccine candidates [SC_RNAseq]

| PRJNA853803 | ENA

Transcriptome atlas of injection site response reveals initial mechanisms of mRNA vaccine immunity

Project description:Precise immunological mechanisms of mRNA vaccines have still not been fully elucidated, especially the initial immune responses at the injection site. Here, by constructing a single-cell atlas of injection site responses of mRNA vaccine, we show that stromal inflammatory responses and type I interferon responses dominate initial transcriptional reactions elicited by mRNA vaccines at the injection site. Tracking down the fates of the delivered mRNA revealed that injection site fibroblasts are highly enriched with the delivered mRNA, and they express IFN-β specifically in response to the mRNA component, not to the LNP. Accordingly, migratory dendritic cells highly expressing interferon stimulated genes (mDC_ISG) were found specifically in muscle and draining lymph nodes of mRNA vaccine injected mice, compared to the empty LNP injected mice. Co-administration of IFN-β and LNP robustly induced mDC_ISGs at the injection site and substantially enhanced antigen-specific CD8 T cell responses. Collectively, these data elucidate earliest mechanisms of the mRNA vaccine and highlight the underappreciated immunogenic role of the mRNA component in the mRNA vaccine.

2023-12-14 | GSE239574 | GEO

The immune response differences of rats induced using RBD3-Fc mRNA vaccines inoculated intradermally by NFIS and intramuscularly by needles

Project description:The immune response differences of rats induced using RBD3-Fc mRNA vaccines inoculated intradermally by NFIS and intramuscularly by needles

| PRJNA1219480 | ENA

Effect of mRNA vaccine on Epigenetic and Transcriptomic Profiles of Kupffer Cells (RNA-Seq)

Project description:The result show that an mRNA/LNP vaccine induced significant numbers of differentially expressed genes (DEG). The analysis identified 123 DEGs between control PBS and mRNA/LNP vaccinated groups where 23 genes and 100 genes were upregulated and downregulated, respectively, in the mRNA/LNP group. To understand the biological changes from the transcriptomic data, gene set enrichment analysis (GSEA) was performed using the whole transcriptome data set. GSEA identified the biological pathways associated with interferon gamma response and protein secretion as the top two ‘Hallmark’ gene sets enriched in OVA mRNA/LNP group, compared to PBS group.

2024-11-06 | GSE267045 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data